TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases. The company operates the Deep Biology Platform, a drug discovery and design platform that integrates tissue-level insights into human biology and Treg function to identify and characterize therapeutic targets, using Computational Mapping, which uses in silico tools and a human tissue bank and atlas of human Treg gene expression to identify pathways in tissue immune regulation; the Treg Atlas, which recreates tissue states in Tregs and reprograms blood-derived Tregs to recreate human tissue-specific pathways in vitro for target validation; and the Phenotypic Assay Cascade, a suite of high-throughput functional fingerprinting assays that test targets across donors and inflammatory contexts. The company develops TRB-061 an investigational tumor necrosis factor receptor 2 (TNFR2) agonist and fragment crystallizable-fusion (Fc-fusion) protein designed to selectively agonize TNFR2 to activate and expand Tregs in inflamed tissues. The company also develops TRB-071, an agonist designed to augment tissue Tregs and block an inflammatory signaling pathway, for inflammatory bowel disease. Additionally, it advances TRB-051, a partnered modulator of immune effector cells, for autoimmune and inflammatory diseases including lupus with cutaneous involvement. The company also advances preclinical-stage programs addressing tissue Treg biology informed by the Deep Biology Platform. TRex Bio, Inc. was incorporated in 2018 and is based in South San Francisco, California.